February 19, 2025 PUBLICATION ALERT: iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA Read about PUBLICATION ALERT: iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA
February 11, 2025 Acuitas Therapeutics Named One of BC’s Top Employers of 2025 Read about Acuitas Therapeutics Named One of BC’s Top Employers of 2025
February 6, 2025 PUBLICATION ALERT: High-throughput quantification and characterization of dual payload mRNA/LNP cargo via deformulating size exclusion and ion pairing reversed phase assays Read about PUBLICATION ALERT: High-throughput quantification and characterization of dual payload mRNA/LNP cargo via deformulating size exclusion and ion pairing reversed phase assays
January 30, 2025 PUBLICATION ALERT: Restoring hematopoietic stem and progenitor cell function in Fancc−/− mice by in situ delivery of RNA lipid nanoparticles Read about PUBLICATION ALERT: Restoring hematopoietic stem and progenitor cell function in Fancc−/− mice by in situ delivery of RNA lipid nanoparticles
December 10, 2024 Acuitas Scientist Presented at 3rd LNP Immunogenicity & Toxicity Summit Read about Acuitas Scientist Presented at 3rd LNP Immunogenicity & Toxicity Summit
November 21, 2024 Acuitas Therapeutics Named One of Canada’s Most Admired™ Corporate Cultures by Waterstone Read about Acuitas Therapeutics Named One of Canada’s Most Admired™ Corporate Cultures by Waterstone
November 20, 2024 Acuitas Therapeutics Honoured With Philanthropic Award Read about Acuitas Therapeutics Honoured With Philanthropic Award
November 18, 2024 Acuitas Scientists Highlight Next Generation LNP Technology at International mRNA Health Conference Read about Acuitas Scientists Highlight Next Generation LNP Technology at International mRNA Health Conference
October 8, 2024 PUBLICATION ALERT: Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA Read about PUBLICATION ALERT: Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA
July 8, 2024 Christopher Sweeney Named Executive Director, Intellectual Property Read about Christopher Sweeney Named Executive Director, Intellectual Property
May 3, 2024 Acuitas Poster Presentations at ASGCT Annual Meeting Read about Acuitas Poster Presentations at ASGCT Annual Meeting
April 11, 2024 Acuitas Therapeutics Named One of Canada’s Top Small & Medium Employers of 2024 Read about Acuitas Therapeutics Named One of Canada’s Top Small & Medium Employers of 2024